Tumor vaccines in 2010: Need for integration

被引：27

作者：

Koos, David ^{[1
]}

Josephs, Steven F. ^{[1
]}

Alexandrescu, Doru T. ^{[2
]}

Chan, Ray Chun-Fai ^{[3
]}

Ramos, Famela ^{[1
]}

Bogin, Vladimir ^{[4
]}

Gammill, Vincent ^{[5
]}

Dasanu, Constantin A. ^{[6
]}

De Necochea-Campion, Rosalia ^{[7
]}

Riordan, Neil H. ^{[8
]}

Carrier, Ewa ^{[7
]}

机构：

[1] Entest BioMed, San Diego, CA USA

[2] Georgetown Dermatol, Washington, DC USA

[3] Bioquant, San Diego, CA USA

[4] Cromos Pharma Serv, Longview, WA USA

[5] Ctr Study Nat Oncol, Del Mar, CA USA

[6] St Francis Hosp & Med Ctr, Dept Hematol & Med Oncol, Hartford, CT USA

[7] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[8] Medistem Inc, San Diego, CA USA

来源：

CELLULAR IMMUNOLOGY | 2010年 / 263卷 / 02期

关键词：

Cancer immunotherapy; Therapeutic vaccine; Immunological tolerance; REGULATORY T-CELLS; ENDOTHELIAL GROWTH-FACTOR; IMMATURE DENDRITIC CELLS; VASCULAR LEAK SYNDROME; HEPATOCELLULAR-CARCINOMA PATIENTS; HIGH-DOSE INTERFERON-ALPHA-2B; NECK-CANCER PATIENTS; COLLAGEN-INDUCED ARTHRITIS; COLONY-STIMULATING FACTOR; RECEPTOR ZETA-CHAIN;

D O I：

10.1016/j.cellimm.2010.03.019

中图分类号：

Q2 [细胞生物学];

学科分类号：

071013 [干细胞生物学];

摘要：

Induction of tumor-specific immunity is an attractive approach to cancer therapy, however to date every major pivotal trial has resulted in failure While the phenomena of tumor-mediated immune suppression has been known for decades, only recently have specific molecular pathways been elucidated, and for the first time, rationale means of intervening and observing results of intervention have been developed In this review we describe major advances in our understanding of tumor escape from immunological pressure and provide some possible therapeutic scenarios for enhancement of efficacy in future cancer vaccine trials (C) 2010 Elsevier Inc All rights reserved.

引用

页码：138 / 147

页数：10

共 191 条

[1]

ADLER A, 1980, CANCER-AM CANCER SOC, V45, P2074, DOI 10.1002/1097-0142(19800415)45:8<2074::AID-CNCR2820450814>3.0.CO

[2]

2-K

[3]

Acute scurvy during treatment with interleukin-2 [J].